Drugmakers Novo Nordisk and Eli Lilly are battling it out in the GLP-1 weight loss market. The pill version of Novo Nordisk's Ozempic has reignited competition between theses two fierce rivals. Meanwhile, another major presence in the medical world -- device maker Intuitive Surgical (NASDAQ: ISRG) -- continues to chug along. And it looks set to do so regardless of which drug company wins the GLP-1 race. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best sto ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. By the numbers   FY26 Q3 revenue: $9.02 billion 8.7% growth year over year   Cardiovascular revenue: $3.46 billion Nearly 14% growth year over year   Diabetes revenue: $796 million Nearly 15% growth year over year Medtronic said Tuesday that a surgeon completed the first U.S. procedure for its Hugo robotic surgery system, shortly after the company received ...

Key Points Intuitive pre-announced sales results for Q4 today -- and growth is slowing down. Full-year and Q4 earnings results won't come out for another week. 10 stocks we like better than Intuitive Surgical › Intuitive (NASDAQ: ISRG) stock (the robotic surgery company formerly known as "Intuitive Surgical") tumbled 5.8% through 11 a.m. ET Wednesday despite pre-announcing a sales beat ahead of official Q4 earnings. Analysts expect Intuitive to report $2.7 billion in quarterly sales, but Intuitive ...

Core Insights - Intuitive Surgical operates a focused business model centered around its da Vinci surgical robot, which is a leading medical device in the industry [2][3] - Despite robust demand for da Vinci systems, Intuitive Surgical's reliance on a single product exposes it to stock volatility, making it less appealing for conservative investors [3][4] - Medtronic presents a diversified alternative, offering exposure to surgical robots while also operating in various medical sectors, which may be more suitable for conservative investors [6][10] Company Performance - Intuitive Surgical has 10,488 da Vinci robots globally, marking a 14% year-over-year increase, with surgeries performed by these robots up 17% year-over-year [3] - Medtronic is recovering from a challenging period, with its fiscal first quarter of 2026 showing an 8.4% revenue growth and 4.8% organic sales growth [8] Investment Considerations - Medtronic offers a nearly 3% dividend yield, significantly higher than the S&P 500's 1.2% and the healthcare sector's average of 1.7%, making it attractive for dividend-seeking investors [9][10] - Intuitive Surgical does not provide a dividend, which may deter conservative investors looking for income [9] Long-term Outlook - Intuitive Surgical is recognized as a well-run business with a promising long-term outlook, but its stock may not suit all investors due to its volatility [11]